ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,39
-0,35%
S&P 500
5.116,17
0,32%
Dow Jones
38.386,09
0,38%
Euro vs US Dollar
1,0707
-0,08%
Bitcoin
63.156,92
-1,07%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Nevro Corp (NVRO)

  7. Nevro Corp (NVRO) News

NVRO Nevro Corp

11,42
0,00 (0,00%)
30 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Nevro Corp NVRO NYSE Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 11,42 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
11,42
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.4.202414:30PRNUSNevro to Report First-Quarter 2024 Financial Results and..
11.3.202421:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202421:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202421:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202421:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202421:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202422:10PRNUSNevro Receives FDA 510(k) Clearance to Use SI Fixation..
23.2.202423:08EDGAR2Form S-8 - Securities to be offered to employees in employee..
22.2.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
21.2.202422:11EDGAR2Form 8-K - Current report
21.2.202422:09EDGAR2Form 8-K - Current report
21.2.202422:06PRNUSNevro Enters Into Cooperation Agreement With Engaged Capital
21.2.202422:05PRNUSNevro Reports Fourth-Quarter and Full-Year 2023 Financial..
14.2.202421:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202421:38EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01.2.202422:30PRNUSNevro Announces Consensus Statement Supporting..
29.1.202422:30PRNUSNevro to Report Fourth-Quarter and Full-Year 2023 Financial..
18.1.202422:15PRNUSNevro Announces Positive Coverage Update from Carelon..
17.1.202422:15PRNUSNevro to Highlight 25 Scientific Abstracts at 2024 North..
11.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
10.1.202423:26EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09.1.202414:41EDGAR2Form 8-K - Current report
09.1.202414:30PRNUSNevro Announces Preliminary Fourth-Quarter and Full-Year..
08.1.202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:15PRNUSNevro to Present at 42nd Annual J.P. Morgan Healthcare..
03.1.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.12.202315:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
05.12.202323:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.12.202312:07EDGAR2Form 8-K - Current report
30.11.202323:19PRNUSNevro Announces Acquisition of Vyrsa™ Technologies
30.11.202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.11.202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.11.202313:00PRNUSNevro Delivers Long-Term Relief with High-Frequency Spinal..
15.11.202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202321:07EDGAR2Form 8-K - Current report
01.11.202321:01PRNUSNevro Reports Third Quarter 2023 Financial Results, Provides..
06.10.202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.10.202313:00PRNUSNevro to Report Third Quarter 2023 Financial Results
03.10.202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.9.202313:00PRNUSNew Data Demonstrate the Health Economic Benefits of Nevro's..
06.9.202323:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.8.202322:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NYSE
NVRO
Nevro
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten